期刊文献+

GLP-1及其类似物的胰外作用研究进展 被引量:1

Progress of Extrapancreatic Effects by GLP-1and Its Analogues
下载PDF
导出
摘要 近年来越来越多的研究表明,胰高血糖素样肽1(GLP-1)及其类似物除作用于胰腺β细胞和α细胞从而达到血糖控制以外,尚存在多种生物学效应,从而发挥许多重要的胰腺外作用,包括对心血管系统的保护、降低体重、调节脂代谢、改善胰岛素敏感性,以及对于肾脏、肝脏、肺脏、生殖内分泌等各脏器系统的功能调节作用,甚至具有潜在的抗肿瘤效应,未来可能在多个疾病领域广泛使用。 In recent years, more and more studies showed that GLP-1 and its analogues still have a variety oi biologtcal effects besides their role of glycemic control. In addition to pancreatic beta cells and alpha ceils, they also play many important roles outside the pancreas including the protection of cardiovascular system, reduction of weight, improvement of insulin sensitivity, regulation of lipid metabolism and so on. Effects on renal, liver and the reproductive endocrine system have been reported. To our surprise, GLP-1 and its analogues even have potentially antineoplastic effect. In view of this, GLP-1 and its analogues may be widely used in multiple therapeutic areas in the future.
作者 赵丽娟 蒋琳
出处 《医学与哲学(B)》 2015年第1期68-70,94,共4页 Medicine & Philosophy(B)
关键词 胰高血糖素样肽1 胰腺外作用 心血管 glucagon-like peptide 1, extrapancreatic effects, cardiovascular
  • 相关文献

参考文献27

  • 1刘璇,蒋琳.肠促胰素对2型糖尿病胰岛功能的影响[J].医学与哲学(B),2011,32(5):13-16. 被引量:4
  • 2王春雨,万东君.老年2型糖尿病药物治疗的选择策略[J].医学与哲学(B),2012,33(7):35-36. 被引量:4
  • 3Nikolaidis L A,Mankad S,Sokos G G,et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ven- tricular dysfunction after successful reperfusion E J 1. Circulation, 2004,109(8) : 962- 965. 被引量:1
  • 4Sokos G G,Nikolaidis L A,Mankad S,et al. Glucagon like peptide 1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure[J]. J Card Fail, 2006,12 (9) :694-699. 被引量:1
  • 5Read P A,Khan F Z,Dutka D P. Cardioprotection against ischaemia in- duced by dohutamine stress using glueagon-like peptide-1 in patients with coronary artery disease[J]. Heart,2012,98(5) :408 -413. 2013, 2013,630537. 被引量:1
  • 6Liu J,Liu Y, Chen L, et al. Glucagon-like peptide-1 analog liraglu- tide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway[J]. J Diabetes Res,. 被引量:1
  • 7tolic blood pressure in subjects with type 2 diabetes[J]. Am J Hy- pertens,2010,23(3):334- 339. 被引量:1
  • 8Kim M,Platt M J,Shibasaki T,et al. GLP 1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure[J]. Nat Meal,2013,19(5) :567-575. 被引量:1
  • 9Yerram P,Whaley-Connell A. Novel role for the incretins in blood pressure regulation[J]. Curt Opin Nephrol Hypertens, 2012, 21 (5) :463 -468. 被引量:1
  • 10Meier J J, Gethmann A, G0tze O, et al. Glucagon like peptide 1 a bolishes the postprandial rise in triglyceride concentrations and low ers levels of non-esterified fatty acids in humans[J]. Diabe-tologia, 2006,49(3) :452-458. 被引量:1

二级参考文献33

  • 1中华医学会内分泌学分会.中国成人2型糖尿病HbAlc控制目标的专家共识[c].第九次全国内分泌学术会议,2010. 被引量:3
  • 2Nathan D M, Buse J B, Davidson M Bet al. Management of hyper- glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetes Care,2008,31, 173. 被引量:1
  • 3DeFronzo R A, Ratner R E, Han J et al. Effects of exenatide (ex endin-4) on glycemic control and weight over 30 weeks in met formin-treated patients with type 2 diabetes[J]. Diabetes Care 2005,28, 1092. 被引量:1
  • 4Kendall D M, Riddle M C, Rosenstock Jet al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J]. Dia- betes Care,2005,28, 1083. 被引量:1
  • 5Blonde L, Klein E J, Han Jet al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J]. Diabetes Obes Metab,2006,8, 436. 被引量:1
  • 6Zinman B, Hoogwerf B J, Duran Garcia Set al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial[J]. Ann Intern Med, 2007,146, 477. 被引量:1
  • 7Buse J B, Klonoff D C, Nielsen L Let al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bio- markers in patients with type 2 diabetes: an interim analysis of data from the open- label, uncontrolled extension of three double- blind, placebo- controlled trials[J]. Clin Ther, 2007,29, 139. 被引量:1
  • 8Raun K, von Voss P, Gotfredsen C F et al. Liraglutide, a long acting glucagon- like peptide- 1 food intake in obese candy-fed dase- Ⅳ inhibitor, vildagliptin, 8. analog, reduces body weight and rats, whereas a dipeptidyl pepti- does not[J]. Diabetes,2007,56,. 被引量:1
  • 9Bregenholt S, Moldrup A, Blume N et al. The long-acting gluca- gon-like peptide-1 analogue, liraglutide, inhibits beta-cell ap- optosis in vitro[J]. Biochem Biophys Res Commun, 2005,330, 577. 被引量:1
  • 10Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long- acting human glucagon- like peptide- 1 analog, given as mono therapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabe- tes[J]. Diabetes Care,2007,30, 1608. 被引量:1

共引文献8

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部